Results from both trials were announced at the Union World Conference on Lung Health in Paris, France.
Annually, around 500,000 people develop tuberculosis (TB), an infectious disease caused by a type of bacteria that affects the lungs, that is resistant to multiple antibiotics.
Led by Stellenbosch University in South Africa, with the MRC Clinical Trials Unit (CTU) at UCL responsible for trial management and statistical analysis, the TB-CHAMP trial involved 922 children and adolescents exposed to an adult with MDR-TB in their household.
Results showed that levofloxacin reduced the risk of MDR-TB disease by 56%, with very few side effects reported.
Additionally, after one year, only 1.1% of children developed TB, compared to 2.6% who received a placebo.
UCL researchers further analysed the data from both trials and confirmed that levofloxacin was safe and effective in preventing TB in both adults and children.
Using standard methods as well as a novel Bayesian approach developed by Becky Turner and professor Ian White from the MRC CTU at UCL, across both trials in total, levofloxacin reduced the risk of developing MDR-TB by 60%.
Trinh Duong, MRC CTU at UCL, TB-CHAMP trial statistician and lead for the combined analysis, said: “Combining data from two trial populations using novel methodology developed at UCL may pave the way for combining future paediatric and adult trial data.”
The MDR-TB preventative treatment is due to be considered by an advisory committee of the World Health Organization in December 2023 to consider new recommendations for children and adolescents.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.